Kiniksa Pharmaceuticals, Ltd. (KNSA)

8.64 +0.46 (+5.62%) At close: 04:00PM EDT

Kiniksa Pharmaceuticals, Ltd.

Clarendon House
2 Church Street
Hamilton HM 11
Bermuda

https://www.kiniksa.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 215

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Sanj K. Patel	CEO & Chairman	1.43M	N/A	1970
Mr. Mark Ragosa C.F.A.	Sr. VP & CFO	N/A	N/A	1975
Mr. Eben Tessari	Sr. VP & COO	N/A	N/A	1982
Mr. Michael R. Megna CPA	Chief Accounting Officer & Group VP of Fin.	N/A	N/A	1971
Ms. Mei Jang	Sr. VP of Technical Operations	N/A	N/A	N/A
Rachel Frank	Associate Director of Investor Relations	N/A	N/A	N/A
Mr. Chad Morin	VP, Chief Compliance Officer & Data Protection Officer	N/A	N/A	N/A
Ms. Madelyn Zeylikman	VP, Gen. Counsel & Sec.	N/A	N/A	N/A
Ms. Melissa Manno	SVP & Chief HR Officer	N/A	N/A	N/A
Dr. John F. Paolini	Sr. VP & Chief Medical Officer	N/A	N/A	1965

Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

Corporate Governance

Kiniksa Pharmaceuticals, Ltd.’s ISS Governance QualityScore as of May 1, 2022 is 10. The pillar scores are Audit: 4; Board: 9; Shareholder Rights: 10; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.